Anti oxidant potential of Metformin and Pioglitazone in Type 2 Diabetes Mellitus: Beyond their anti glycemic effect

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 10, Issue 2, 2016, Pages 102-104

  Singh, R K ^a   Gupta, B ^a   Tripathi, K ^a   Singh, S K ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Malondialdehyde (MDA); Metformin; Pioglitazone; Superoxide Dismutase (SOD); Type 2 Diabetes

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; METFORMIN; PIOGLITAZONE; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ADULT; ANTIOXIDANT ACTIVITY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; ANALYSIS OF VARIANCE; BLOOD; COMBINATION DRUG THERAPY; DRUG EFFECTS; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MALONDIALDEHYDE; METFORMIN; MIDDLE AGED; OXIDATIVE STRESS; SUPEROXIDE DISMUTASE; THIAZOLIDINEDIONES;

EID: 84940702679     PISSN: 18714021     EISSN: 18780334     Source Type: Journal    
DOI: 10.1016/j.dsx.2015.08.016     Document Type: Article

References (14)

1. R.L. Engerman, T.S. Kern, and M.E. Larson Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs Diabetologia 37 1994 141 144
2. M. Brownlee The pathobiology of diabetic complications: a unifying mechanism Diabetes 54 2005 1615 1625
3. D. Koya, and G.L. King Protein kinase C activation and the development of diabetic complications Diabetes 47 1998 859 866
4. J.S. Johansen, A.K. Harris, D.J. Rychly, and A. Ergul Oxidative stress and the use ofantioxidants in diabetes: linking basic science to clinical practice Cardiovasc Diabetol 4 2005 5
5. S. Penckofer, D. Schwertz, and K. Florczak Oxidative stress and cardiovascular disease in type 2 diabetes: the role of antioxidants and pro-oxidants J Cardiovasc Nurs 16 2002 68 85
6. T.H. Wierzba Unexpected failure of antioxidant clinical trials Kardiol Pol 63 2005 S472 S482
7. I. Robinson, D.G. de Serna, A. Gutierrez, D.S. Schade, and E. Vitamin in humans: an explanation of clinical trial failure Endocr Pract 12 2006 576 582
8. B.J. Willcox, J.D. Curb, and B.L. Rodriguez Antioxidants in cardiovascular health and disease: key lessons from epidemiologic studies Am J Cardiol 101 2008 75D 86D
9. J.L. Evans, B.A. Maddux, and I.D. Goldfine The molecular basis for oxidative stress- induced insulin resistance Antioxid Redox Signal 7 2005 1040 1052
10. F. Giacco, and M. Brownlee Oxidative stress and diabetic complications Circ Res 107 2010 1058 1070
11. S. Golbidi, S.A. Ebadi, and I. Laher Antioxidants in the treatment of diabetes Curr Diabetes Rev 7 2011 106 125
12. A. Gómez-García, and G.M. Torres Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia Rev Esp Cardiol 60 2007 1242 1249
13. C. Antonio, J. Don, W. Mario, J.E. David, J.G. Kathryn, and H.T. Meng Comparison of Effect of Pioglitazone With Metformin or Sulfonylurea (Monotherapy and Combination Therapy) on Postload Glycemia and Composite Insulin Sensitivity Index During an Oral Glucose Tolerance Test in Patients With Type 2 Diabetes Diabetes Care 28 2005 266 272
14. D. Pavlović, R. Kocić, G. Kocić, T. Jevtović, S. Radenković, D. Mikić, M. Stojanović, and P. Djordjević B. Effect of four-week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes Diabetes Obes Metab 2 4 2000 Aug 251 256